IRIS

TRAIL receptor agonist conatumumab with modified FOLFOX6 plus bevacizumab for first-line treatment of metastatic colorectal cancer: A randomized phase 1b/2 trial / Fuchs, Cs; Fakih, M; Schwartzberg, L; Cohn, Al; Yee, L; Dreisbach, L; Kozloff, Mf; Hei, Yj; Galimi, Francesco; Pan, Y; Haddad, V; Hsu, Cp; Sabin, A; Saltz, L.. - In: CANCER. - ISSN 1097-0142. - (2013). [10.1002/cncr.28353]

TRAIL receptor agonist conatumumab with modified FOLFOX6 plus bevacizumab for first-line treatment of metastatic colorectal cancer: A randomized phase 1b/2 trial.

GALIMI, Francesco;
2013-01-01
2013
TRAIL receptor agonist conatumumab with modified FOLFOX6 plus bevacizumab for first-line treatment of metastatic colorectal cancer: A randomized phase 1b/2 trial / Fuchs, Cs; Fakih, M; Schwartzberg, L; Cohn, Al; Yee, L; Dreisbach, L; Kozloff, Mf; Hei, Yj; Galimi, Francesco; Pan, Y; Haddad, V; Hsu, Cp; Sabin, A; Saltz, L.. - In: CANCER. - ISSN 1097-0142. - (2013). [10.1002/cncr.28353]
1.1 Articolo in rivista
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11388/46412
Citazioni
  • ???jsp.display-item.citation.pmc??? 28
  • Scopus ND
  • ???jsp.display-item.citation.isi??? 54
social impact